NCT03931681: A Study of OKI-179 in Patients With Solid Tumors

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Misc Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with known active central nervous system (CNS) metastases and/or leptomeningeal disease; Patients with prior valproic acid, HDAC, or HSP90 inhibitors

Comments are closed.

Up ↑